Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in differentiated thyroid cancer
NCT03048877Phase 3Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in differentiated thyroid cancer (DTC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT03048877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03048877.